# Measles and rubella elimination country profile Czech Republic



#### Measles elimination status

2015 eliminated 2016 eliminated

Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

## National plan of action

Does the country have a national plan of action? Is it updated? ND

Source: Measles and rubella elimination Annual Status Update report, 2016 ND= Data not available

#### Measles and rubella immunization schedule, 2016

|      | Vaccine | Schedule     | Year of introduction |      |  |
|------|---------|--------------|----------------------|------|--|
| MCV1 | MMR     | 15<br>months | MCV2                 | 1975 |  |
| MCV2 | MMR     | 21<br>months | RCV                  | 1982 |  |
| Me   | No      |              |                      |      |  |

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance

[http://www.who.int/immunization/monitoring\_surveillance/data/en/]
MMR = measles-mumps-rubella-containing vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

#### Definition used for an outbreak

At least two measles or rubella cases including cases with epidemiological links



Source: Measles and rubella elimination Annual Status Update report, 2016

#### Rubella elimination status

2015 eliminated 2016 eliminated


Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

# Demographic information, 2016

| Total population | 10 548 058 |  |  |
|------------------|------------|--|--|
| < 1 year old     | 106 751    |  |  |
| < 5 years old    | 517 000    |  |  |

Source: World Population Prospects: The 2015 Revision, New York, United Nations

# Measles and rubella cases and immunization coverage, 2007-2016




Source: Disease incidence and immunization coverage, WHO, Data and Statistics,

Immunization Monitoring and Surveilance

(http://www.who.int/immunization/monitoring\_surveillance/data/en/) MCV1 = first dose of measles-containing vaccine

MCV2= second dose of measles-containing vaccine

### Confirmed measles cases by month of onset, 2012-2016



Source: CISID2 2016



# Measles and rubella elimination country profile Czech Republic



#### Measles cases by first subnational level, 2016



Source: Measles and rubella elimination Annual Status Update report, 2016

#### Measles genotypes by first subnational level, 2016




Source: MeaNS 2016 (Note: no subnational genotype information available)

Note: The dots in the maps are placed randomly within the administrative regions

Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

# Measles cases by age group and vaccination status, 2016



Source: Measles and rubella elimination Annual Status Update report, 2016

#### Sources of infection, 2016

|                          | Measles | Rubella |
|--------------------------|---------|---------|
| Imported                 | 5       | 0       |
| Import-related           | 1       | 0       |
| Unknown/ Not<br>reported | 0       | 0       |
| Endemic                  | 1       | 0       |

Source: Measles and rubella elimination Annual Status Update report, 2016

#### Information on CRS, 2016



Source: Measles and rubella elimination Annual Status Update report, 2016 CRS = congenital rubella syndrome

# Measles and rubella elimination country profile Czech Republic



## Measles incidence, epidemiologic and virologic characteristics, 2012-2016

|      | Suspected        | C               | Confirmed m    | easles case | Discarded as | Measles         | Genotypes |          |
|------|------------------|-----------------|----------------|-------------|--------------|-----------------|-----------|----------|
|      | measles<br>cases | Labora-<br>tory | Epi-<br>linked | Clincally   | Total        | non-<br>measles | incidence | detected |
| 2012 | ND               | 22              | 4              | 22          | 22           | ND              | 1.0       | D4       |
| 2013 | 31               | 15              | 0              | 0           | 15           | 16              | 0.4       | ND       |
| 2014 | 305              | 221             | 1              | 0           | 222          | 83              | 20.8      | B3,D8    |
| 2015 | 35               | 9               | 0              | 0           | 9            | 9               | 0.6       | D8       |
| 2016 | 2                | 7               | 0              | 0           | 7            | 0               | 0.2       | В3       |

ource: Measles and rubella elimination Annual Status Update report, 2012-2016, and internal communication from country Incidence calculated per 1 million population

## Rubella incidence, epidemiologic and virologic characteristics, 2012-2016

|      | Suspected rubella cases |            |             |           |       | Discarded as    | Rubella   | Genotypes |
|------|-------------------------|------------|-------------|-----------|-------|-----------------|-----------|-----------|
|      |                         | Laboratory | Epi- linked | Clincally | Total | non-<br>rubella | incidence | detected  |
| 2012 | ND                      | 7          | 0           | 0         | 7     | ND              | 0.6       | ND        |
| 2013 | 0                       | 0          | 0           | 0         | 0     | 0               | 0         | NA        |
| 2014 | 2                       | 1          | 0           | 0         | 1     | 1               | 0.1       | ND        |
| 2015 | 0                       | 0          | 0           | 0         | 0     | 0               | 0         | NA        |
| 2016 | 1                       | 0          | 0           | 0         | 0     | 1               | 0         | NA        |

iource: Measles and rubella elimination Annual Status Update report, 2012-2016

#### Measles surveillance and laboratory performance indicators, 2012-2016

|      | Discarded<br>non-<br>measles<br>rate | % 1st sub-<br>national<br>unit with<br>≥ 2<br>discarded<br>cases | % cases with adequate laboratory investiga- tion | % origin of infection known | #<br>specimen<br>tested for<br>measles | % positive<br>for<br>measles | Rate of<br>viral<br>detection | % WHO<br>and<br>proficient<br>labs |
|------|--------------------------------------|--|--|-----------------------------|--|------------------------------|-------------------------------|------------------------------------|
| 2012 | ND                                   | ND   | 100%   | 100%                        | ND                                     | ND                           | ND                            | ND                                 |
| 2013 | 51.6                                 | ND   | 100%   | 80%                         | ND                                     | ND                           | ND                            | ND                                 |
| 2014 | 32.6                                 | ND   | 100%   | 91%                         | ND                                     | ND                           | 35.3%                         | ND                                 |
| 2015 | 0.1                                  | ND   | 100%   | 55.6%                       | 35                                     | 25.7%                        | 20%                           | 100%                               |
| 2016 | NA                                   | NA   | 100%   | 85.7%                       | 22                                     | 45.5%                        | 25%                           | 100%                               |

Source: ASU 2012-2016, MeaNS 2012-2016 and laboratory accreditation results 2012-2016 ND = Data not available; NA= Not applicable

# Rubella surveillance and laboratory performance indicators,

|      | Discarded<br>non-<br>rubella<br>rate | % 1st sub-<br>national<br>unit with<br>\$ 2<br>discarded<br>cases | % cases with adequate laboratory investiga- tion | % origin of infection known | #<br>specimen<br>tested for<br>rubella | % positive<br>for rubella | Rate of<br>viral<br>detection | % WHO<br>and<br>proficient<br>labs |
|------|--------------------------------------|---|--|-----------------------------|--|---------------------------|-------------------------------|------------------------------------|
| 2012 | ND                                   | ND  | 85.7%  | 100%                        | ND                                     | ND                        | ND                            | ND                                 |
| 2013 | NA                                   | NA  | NA   | NA                          | ND                                     | 0%                        | NA                            | ND                                 |
| 2014 | 50%                                  | NA  | 100%   | 100%                        | ND                                     | ND                        | 0                             | ND                                 |
| 2015 | NA                                   | NA  | NA   | NA                          | ND                                     | 0%                        | NA                            | 100%                               |
| 2016 | ND                                   | NA  | NA   | NA                          | 1                                      | 0%                        | NA                            | 100%                               |

Source: ASU 2012-2016, RubeNS 2012-2016 and laboratory accreditation results 2012-2016 ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight

#### RVC comments, based on 2016 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in the Czech Republic in 2016 and confirmed that measles and rubella elimination has been sustained. The RVC commends the National Verification Committee (NVC), national health authorities and public health system on this achievement, but emphasizes to the NVC the need for more comprehensive data in the ASU, especially in regards to surveillance performance. The RVC also urges both the NVC and national health authorities to adjust routine procedures, in line with WHO recommendations and guidelines, to enable adequate surveillance and to improve the collection and submission in the ASU of immunization coverage data. The RVC is concerned that, based on the limited data currently available in the ASU, surveillance performance appears to be suboptimal and it is not possible to assess routine immunization coverage in 2016.

Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)

#### Surveillance performance indicators and targets

- a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- b. % cases with adequate laboratory investigation: ≥ 80%
- c. % origin of infection known: ≥ 80%
- d. Rate of viral detection: ≥ 80%



ND = Data not available: NA= Not applicable

Incidence calculated per 1 million population ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory